Search PubMed⌕ Search

Biomedical subjects

A L Hume

Publications and source records attributed to A L Hume.

At least 19 recordsLinked to original sources
PubMed1995

Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared with nonusers.

OBJECTIVE: Our purpose was to investigate whether selection of healthy women for postmenopausal estrogen therapy may confound observational studies of estrogen use and cardiovascular disease risk. STUDY DESIGN: Data were obtained from baseline (1981 to 1984) and follow-up (1990 to 1992) health surveys of two cohorts randomly selected from communities in southeastern New England. At follow-up postmenopausal women > or = 40 years old were categorized as current users (n = 70) or nonusers (n = 772) of noncontraceptive estrogen. Users and nonusers were compared on both prior characteristics from the baseline surveys and current characteristics measured at follow-up by use of analysis of covariance. RESULTS: Prior levels of total and high-density lipoprotein cholesterol, body mass index, and blood pressure were similar for estrogen users and nonusers. Estrogen users were less likely to have smoked and more likely to have had their cholesterol checked and to exercise regularly. These differences were more pronounced for current characteristics than for baseline characteristics. CONCLUSIONS: Selection of healthy women for treatment may not fully explain the apparent protective effect of estrogen replacement on cardiovascular risk. However, more healthy profiles among estrogen users may inflate the apparent benefit of treatment in observational studies.

Adult↗
PubMed1995

Is the use of psychotropic drugs associated with increased risk of ischemic heart disease?

Earlier reports of associations between panic disorder, depression, and ischemic heart disease have not evaluated the role of the drugs used to treat these conditions. As part of a larger study on reducing cardiovascular disease in an entire community, we estimated the association between psychotropic drugs and ischemic heart disease in a large community-based population using a cohort study design. We defined exposure as current use of psychotropic medications at the time of the health interview. We determined ischemic heart disease by International Classification of Diseases, 9th revision, Clinical Modification, codes and by an epidemiologic algorithm using clinical diagnostic criteria. An elevated risk for clinically significant ischemic cardiac events was moderately associated with benzodiazepine use [relative risk (RR) = 2.0; 90% confidence interval (CI) = 1.1-3.9] and strongly associated with antidepressant use (RR = 5.7; 90% CI = 2.6-12.8), although the latter estimate was based on only six antidepressant users who had an ischemic event.

Adult↗
PubMed1994

High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease.

Pharmacologic doses of folate, in the absence of clinical folate deficiency, can reduce plasma levels of the putatively atherothrombotic amino acid, homocysteine (H(e)). Data suggesting that H(e) may accumulate in experimental scurvy prompted us to explore the efficacy of high dose ascorbate supplementation as a H(e)-lowering treatment, in the absence of clinical ascorbate deficiency. A randomized, placebo-controlled trial of 12 weeks of high dose (4.5 g/day) ascorbate supplementation was completed by 44 patients with established coronary heart disease. No significant change in mean fasting total plasma H(e) levels was demonstrable despite a marked increase in mean fasting plasma ascorbate levels amongst those patients randomized to active treatment. Ascorbate supplementation to prevent the development of fasting hyperhomocysteinemia may only be relevant at scorbutic levels of plasma ascorbate.

Ascorbic Acid↗
PubMed1994

Prevalence of hypertension, dyslipidemia, and dyslipidemic hypertension.

BACKGROUND: It has been proposed that dyslipidemic hypertension is part of a distinct metabolic syndrome related to insulin resistance. This paper describes the prevalence and cross-sectional relations of dyslipidemic hypertension in a population-based sample of men and women. METHODS: In two southeastern New England communities, 11,199 randomly selected participants were evaluated as part of a cross-sectional surveillance program of coronary heart disease risk factors between 1981 and 1990. RESULTS: The frequency of dyslipidemia was 38% and of hypertension was 26.5%; the conjoint frequency (dyslipidemic hypertension) was 15.0%, which is 1.49 times the expected value if the two diseases were independent P < .05). Using a discrete multivariate model, dyslipidemia and hypertension were associated with sex, obesity, and diabetes mellitus. The excess association of dyslipidemic hypertension, compared with individual effects of dyslipidemia and hypertension, was not related to these factors. CONCLUSIONS: This study suggests that dyslipidemic hypertension is common but may not be a unique entity associated with a distinct metabolic syndrome.

Adolescent↗
PubMed1993

Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities.

Correlates and prevalence of current postmenopausal estrogen use were examined in two southeastern New England communities for the period 1981 through 1990. Data were obtained from five biennial cross-sectional household health surveys, with current use of postmenopausal estrogen determined by inspection of medication bottles. Analysis included 3,279 women aged 40-64 years, of whom 2,215 (67.6%) were postmenopausal. The prevalence of estrogen use among all postmenopausal women increased from 5.3% (95% confidence interval (CI) 3.2-7.4) in 1981-1982 to 10.9% (95% CI 7.5-14.4) in 1989-1990. Among women with surgical menopause, prevalence increased from 11.4% (95% CI 6.6-16.2) to 20.3% (95% CI 13.6-27.0), while use among women with natural menopause increased from 1.5% (95% CI 0.04-2.9) to 3.5% (95% CI 0.74-6.2). Logistic regression was used to compute age-adjusted prevalence of estrogen use according to demographic characteristics and cardiovascular risk factors. Postmenopausal estrogen use was positively associated with income, and a positive trend with education was suggested. Estrogen use was positively associated with high density lipoprotein cholesterol and was inversely associated with body mass index. Nonsmokers, women who exercised at least once per week, and women who reported having their cholesterol checked in the past year were more likely to use estrogen. These findings suggest that estrogen users have a more healthy profile than do nonusers. In addition, the prevalence of postmenopausal estrogen use appears to be substantially lower in women with natural versus surgical menopause throughout the period studied.

Adult↗
PubMed1993

Pharmacotherapy in family medicine: current issues and strategies.

Pharmacotherapy is an increasingly complicated area for the primary care physician. However, many resources, techniques, and technologies are now available that may minimize complications, improve compliance, and maximize the benefits patients derive from the use of their medications.

Drug Prescriptions↗
PubMed1991

A successful physician training program in cholesterol screening and management.

METHOD: Thirty-six resident physicians received a blood cholesterol training program which included training in blood cholesterol screening using a fingerstick method and a desktop analyzer, diet assessment and counseling, and a management protocol for follow-up diet and drug treatment. The program also included feedback to residents about their blood cholesterol screening activity, incentives, and biweekly articles in the department newsletter. RESULTS: Between 1986-1987 (baseline) and 1987-1988 (intervention), the percentage of the target patient population (ages 20-65 years, nonpregnant, not screened in the previous year) that was screened for hypercholesterolemia in this primary care practice increased from 16.2 to 23.2% [rate difference (RD) = 7.0; 95% confidence interval (CI) = 4.75-9.25]. The mean value of the screening tests decreased from 5.36 mmol/liter (207.2 mg/dl) to 5.08 mmol/liter (196.6 mg/dl; t = 2.98, P = 0.003) and the percentage of the population screened needing further evaluation decreased from 36.8 to 27.6% (RD 9.2; CI = 2.00-14.00). In the intervention year, compared with the baseline year, patients with a borderline blood cholesterol and cardiovascular risk factors were more likely to have a follow-up test (28.8% vs 11.9%, RD = 16.9; 95% CI = 0.80-33.00) and the low-density lipoprotein cholesterol test was used less for screening (8.2% vs 19.4%, P less than 0.0001). Conclusion. We conclude that this program was effectively integrated into a busy primary care practice, leading to improvement in blood cholesterol screening and management practices.

Adult↗
PubMed1990

Severe hyponatremia: an association with lisinopril?

A 63-year-old white woman with a history of hypertension and chronic obstructive pulmonary disease presented to the emergency room with worsening shortness of breath, anorexia, coughing, increased thirst, and leg edema of two weeks' duration. Medications included lisinopril 10 mg/d, which had been started six weeks earlier, sustained-release theophylline 300 mg q12h, and an albuterol inhaler. The lisinopril was discontinued on admission. Serum sodium concentration was 109 mmol/L; the osmolality of the blood and of the urine were 253 mOsmol and 438 mOsmol, respectively, with a specific gravity of 1.025 and a urine sodium of 17 mmol/L. The hyponatremia initially was considered to be the syndrome of inappropriate antidiuretic hormone secretion in response to the patient's suspected pneumonia. Due to worsening blood pressure, lisinopril was restarted and the serum sodium concentration dropped from 134 to 126 mmol/L. Evaluation of the patient's hyponatremia included assessment of thyroid, adrenal, hepatic, and cardiac function that were within normal limits. The patient was discharged on the following medications: sustained-release theophylline 300 mg tid, prednisone 10 mg/d, albuterol inhaler 2 puffs q6h, and sustained-release verapamil 240 mg/d for blood pressure control. Her serum sodium concentration has remained between 135 and 140 mmol/L during hospitalizations for exacerbations of chronic obstructive pulmonary disease and for pneumonias 10 and 12 months after discharge.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed1990

Clinical pharmacists in family practice residency programs.

A project was undertaken to determine the number, specific activities, and demographics of clinical pharmacists directly involved with residency programs in family practice. A survey was mailed to the directors of all 381 family practice residencies, with a request either to forward it to the participating pharmacist or to return the survey if a pharmacist did not directly participate in the teaching program. With two mailings, responses were received from 85.3% of the residencies, with 80 pharmacists completing surveys. While the involvement of pharmacists in family practice residencies was similar to that reported in a survey 9 years ago, academic appointments and funding, in whole or in part by a college of medicine, had increased. This increased involvement may represent an acknowledgment by medical educators in family practice of the value of pharmacists participating in residency programs.

Adult↗
PubMed1989

Angiotensin-converting enzyme inhibitor-induced cough.

A 65-year-old woman started taking enalapril 2.5 mg daily for hypertension. Twelve days later she complained of a persistent, dry cough. Due to the coughing and a preexisting cystocele, she developed stress incontinence and a marked decline in her functional status. The coughing and incontinence resolved with the discontinuation of enalapril. During a subsequent hospitalization the patient received captopril 6.25 mg twice daily for congestive heart failure. Within 24 hours the dry cough recurred. It resolved with the discontinuation of the drug. Cough is a symptom that is generally not recognized as a drug side effect. However, increasing numbers of case reports document angiotensin-converting enzyme inhibitor-induced cough. Although the actual frequency and mechanism are currently unknown, the dry cough typically begins early in the course of therapy. It may be specific to this pharmacologic class rather than to one individual agent. Age and sex may be contributing factors. While cough has been considered a minor side effect, unnecessary hospitalizations and inappropriate treatments may easily result. Even minor adverse reactions may have an impact on a patient's quality of life.

Aged↗
PubMed1989

Applying quality of life data in practice. Considerations for antihypertensive therapy.

Quality of life issues have become increasingly important in tailoring antihypertensive therapy to individual patients. The application of quality of life data to the practice setting is frequently difficult, however. The effective use of this information requires an understanding of its definition and measurement, as well as of study methods. Quality of life findings may be specific to particular disease states, patient populations, and pharmacologic agents. The addition of hydrochlorothiazide to concurrent methyldopa, propranolol, or captopril therapy has been reported to reduce patients' overall sense of well-being. beta-Adrenergic blockers may exert either positive or negative effects on quality of life. Angiotensin-converting enzyme (ACE) inhibitors may have positive effects on quality of life; however, the cost of therapy is an important consideration. Information on calcium antagonists is limited. The findings of the Treatment of Mild Hypertension Study (TOMHS) may eventually provide comparative quality of life data on the four first-line antihypertensive therapies.

Adult↗
PubMed1988

Evoked potentials in suspected multiple sclerosis: diagnostic value and prediction of clinical course.

Pattern visual, somatosensory and brainstem auditory evoked potentials (EPs) of 14 patients with definite multiple sclerosis, 222 patients suspected of having multiple sclerosis, 26 patients with isolated optic neuritis and 40 patients with a chronic not diagnosed neurologic disorder, were compared with their clinical diagnoses on 2 1/2-year follow-up. In the MS suspects, an EP abnormality demonstrating a clinically silent lesion in any modality (65 patients) was associated with a 71% chance of clinical deterioration (48% chance of definite MS within the follow-up period). Normal EPs (121 patients) were associated with a 16% chance of deterioration (4% chance of definite MS). EPs in patients in whom the only abnormalities confirmed known lesions (36 patients) did not predict follow-up status. Visual EPs demonstrated clinically silent lesions more frequently than somatosensory and auditory EPs (22%, 12% and 5% of patients). Only one of the patients with optic neuritis and 3 of the chronic not diagnosed group had EPs demonstrating clinically silent lesions. CSF and NMR studies also correlated with follow-up in subseries of the patients.

Adolescent↗